Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
In Part 1 of this series, we provided an overview of the quantum sensing landscape, including the core technologies, the investment thesis driving interest in the sector, key public and private funding options, and the commercial and defense applications accelerating demand. Part 2 turns to the legal and regulatory infrastructure needed to commercialize and protect those technologies, including intellectual property (IP) strategy; technology transfer and licensing considerations; trade secrets; patents; software and data protection; government contracting compliance; cybersecurity; export controls; foreign ownership, control or influence (FOCI); the Committee on Foreign Investment in the United States (CFIUS); and related national security planning. Look for the final Part 3 of the series, which will discuss employment and talent management considerations for quantum sensing companies, including export-control constraints on hiring, security clearances, workforce structuring, and immigration strategy.
Quantum sensing companies should adopt a layered IP strategy early on by, for example, considering combining patents, trade secrets, and data rights to protect core innovations while pursuing both commercial and defense markets. IP starts at the “cocktail napkin” stage of development and should not be viewed as a cost sink, but as a primary vehicle for monetizing new technology. In the defense space, it is even more critical because missteps in contracting or disclosures can inadvertently grant the government broad IP and data rights in key technologies. Before sourcing foundational IP from external research partners (e.g., national labs or academic institutions), startups should consider key differences in ownership and government-use rights, publication and confidentiality expectations, export-control and national security constraints, licensing/sublicensing fees and, if applicable, equity structures.
The maturity of each institution’s technology transfer process is a major consideration and should be diligenced early on, as the sophistication of licensing processes can vary significantly between institutions and may cause material delays in securing and implementing critical IP rights. While some institutions offer boilerplate license agreements that are sold as an efficient means to obtain an IP license, the devil is often in the details, and seemingly minor provisions on field of use, sublicensing, government march-in rights, patent maintenance costs, royalties, and ownership of improvements can materially affect long-term value. A poorly structured IP license can therefore create long-term constraints on financing, partnering, and exit opportunities, so it is critical to negotiate terms that align with realistic commercialization timelines, favoring longer development windows that account for technical risk, regulatory hurdles, slow-moving defense and space acquisition cycles, and variability in the sophistication and responsiveness of licensing offices.
Trade secrets offer a low-cost, early-stage shield, but trade secret owners must take reasonable steps to keep information confidential. They should implement clear internal controls and policies (e.g., NDAs, proprietary information and invention assignment agreements, access restrictions, confidentiality markings, document tracking, etc.) to limit outsider access and prevent employee misuse or disclosure. In government-facing work, companies must be diligent about markings: proposals, deliverables, and even classified responses to requests for information (RFIs) and requests for proposals (RFPs) should carry appropriate proprietary legends to preserve intellectual property rights. Finally, owners should keep an IP register tracking what was shared, with whom, and under what restrictions.
Patents generally provide stronger and more durable protection than trade secrets, and they offer a clearer path toward monetization. IP owners should consider filing provisional applications on differentiating hardware, control systems, and calibration or error-mitigation methods before making external disclosures and should exercise disclosure discipline in pitches and proposals. In government contracting, they should clearly distinguish background IP from foreground IP and negotiate data rights terms carefully to avoid granting “unlimited rights” in core technology.
Quantum sensing companies that treat software and data as first-class IP assets gain a decisive competitive edge. For example, companies often consider protecting control firmware, timing and synchronization logic, and signal extraction and fusion algorithms, and may use modular licensing so that integrators receive application programming interfaces (APIs) without access to core source code.
Similarly, datasets, environmental models, and calibration libraries are frequently licensed separately from hardware. In both commercial and government settings, careful use of markings and legends on these assets can help clarify the intended scope of rights and reduce the risk of unintentionally granting broader rights than expected.
Copyright and branding also play a meaningful role in IP strategy. Companies often consider marking and registering software and key technical materials where it is practical to do so, and may pursue trademark protection for product families, modules, and company branding to support commercialization and differentiation in the market.
Common pitfalls in this space can include granting broad rights by default, disclosing enabling technical details too early, over-relying on trade secrets in programs that demand significant transparency, neglecting data-rights markings on deliverables, or allowing open-source obligations to creep into proprietary code. Developing and following a structured IP playbook can help protect differentiating technology while preserving flexibility to scale across both defense and commercial markets.
In practice, founders should (1) establish a documented IP strategy (covering trade secret measures, and disclosure and provisional filing procedures); (2) enforce data-confidentiality hygiene (NDAs, markings, access controls); (3) file provisional patent applications before external disclosures; (4) use Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) and other contracting templates with consistent data-rights legends and clear background/foreground IP definitions; and (5) set university and lab collaboration terms upfront (including ownership, publication delay, and option rights).
Quantum sensing companies pursuing SBIR/STTR or other government funding should plan for the various compliance obligations that accompany doing business with the U.S. government from the outset. Even at Phase I, awards often incorporate federal funding compliance requirements that affect how the company must track time and costs, manage subcontracts (either as a prime or a subcontractor itself), and protect technical data. Accordingly, companies seeking government awards should treat compliance as a core part of their business strategy.
Quantum sensing companies looking to do business with the U.S. government should establish clear timekeeping and cost policies, a subcontracting checklist to manage flow-downs, and, among other things, a data rights protocol that ensures deliverables carry the required information marking conventions to limit government data rights. Cybersecurity is another early compliance concern — many awards involve Controlled Unclassified Information (CUI), triggering baseline controls aligned with federal standards (e.g., documented system security plans, incident response procedures, National Institute of Standards and Technology (NIST) Special Publication 800-171 requirements, and vendor due diligence). Further, the integration of quantum sensing technologies into defense applications presents significant challenges under the Department of Defense/War’s (DoD/W) Cybersecurity Maturity Model Certification (CMMC)2.0 framework.[1] The primary concerns are data protection, specialized asset management, and the rapid pace of technological development compared to often-sluggish regulatory cycles, as quantum sensing experiments may generate CUI as high-volume, high-fidelity data with national security relevance. Because many quantum platforms depend on specialized hardware, companies should also develop asset inventories and change-control procedures that account for these nontraditional components, and document how they are secured, monitored, and maintained within their cybersecurity domains. Among other compliance obligations, companies should anticipate publication and public release restrictions, distribution statements on reports, and domestic sourcing or manufacturing preferences that can significantly impact prototyping and supply chains.
National security compliance overlays may become more pronounced for quantum sensing dual-use technologies with defense and surveillance capabilities. For example, the U.S. Department of the Air Force’s (DAF) AFWERX program has used the SBIR and STTR authorities to support dual-use technology companies, including in advanced sensing and autonomy.[2] Before submitting an SBIR/STTR proposal (especially with an agency like the DAF’s AFWERX), companies should screen their technology, supply chains, and collaborations for potential foreign entity of concern (FEOC) and export control issues, and classify hardware, software, data, and encryption to determine whether licenses are required for foreign nationals, overseas testing, or cloud access. Companies should heavily scrutinize any foreign investment relationship or opportunity and weigh each against FOCI risk exposure. Much of this work may require mitigation measures, facility or personnel clearances (FCL/PCL), and limitations on foreign participation stemming from FOCI concerns or FCL/PCL requirements.[3] Foreign investment can also create risks and obligations with CFIUS[4] and under the International Traffic in Arms Regulations (ITAR).[5] Companies should be prepared for program-specific security requirements (e.g., safeguarding sensitive geospatial data, handling test results as CUI, and rapid cyber incident reporting).
Finally, quantum companies should build a commercialization plan that reconciles dual-use ambitions with compliance, which may include: (i) using information access controls to segregate defense work from commercial business; (ii) maintaining and managing traceable configuration baselines; and (iii) incorporating import/export/sanctions screening and supplier integrity checks so national security obligations do not unnecessarily stall scaling efforts.
[1] Note, CMMC 2.0 is partially in effect at this time. On July 13, 2026, the DoD/W announced the immediate suspension of CMMC 2.0’s Phase II requirements, which were scheduled to take effect on November 10, 2026. Despite this pause, CMMC Level 1 (Self) and Level 2 (Self) self-assessment requirements remain in effect. For more on the implications of the CMMC 2.0 Phase II pause, please see our recent article on the matter: Years in the Making, Suspended in a Day: DoD/W Halts CMMC Phase II but Keeps Baseline Cybersecurity Obligations – Troutman Pepper Locke.
[2] See AFWERX, About AFWERX, https://afwerx.com (describing AFWERX’s role in accelerating dual-use innovation through Air Force and Space Force SBIR/STTR).
[3] See Defense Counterintelligence and Security Agency, Foreign Ownership, Control or Influence (FOCI), https://www.dcsa.mil/FOCI.
[4] Committee on Foreign Investment in the United States, CFIUS, https://www.cfius.gov/.
[5] Such foreign investment and export control considerations are addressed in more detail below.
This just in
Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Speaking Engagements
Performance on Trial: The Construction Manager’s Standard of Care Examined from All Angles
December 2, 2026 | 4:15 PM – 5:30 PM ET
The Hyatt Regency Huntington Beach
Huntington Beach, CA
Speaking Engagements
ACI’s 31st Annual Conference on Drug & Medical Device Litigation – 2026
December 2 – 3, 2026
New York Marriott Marquis
1535 Broadway, New York, NY 10036
Speaking Engagements
Entering the Defense Market: USA, Canada, Ukraine, UK, Germany, Poland
November 19, 2026 | 3:00 PM – 5:00 PM CT
Virtual